The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.
 
Leon Furchtgott
Employment - GNS Healthcare
 
David Swanson
Employment - GNS Healthcare
 
Boris Hayete
Employment - GNS Healthcare
Leadership - GNS Healthcare
Stock and Other Ownership Interests - GNS Healthcare
Research Funding - GNS Healthcare
 
Iya Khalil
Employment - GNS Healthcare
Leadership - GNS Healthcare
Stock and Other Ownership Interests - GNS Healthcare
Patents, Royalties, Other Intellectual Property - GNS Healthcare
 
Diane Wuest
Employment - GNS Healthcare
 
Kelly Rich
Employment - GNS Healthcare
Stock and Other Ownership Interests - GNS Healthcare
 
Andrew B. Nixon
Consulting or Advisory Role - Cerulean Pharma; Novartis; Pfizer
Research Funding - Acceleron Pharma; Amgen; Genentech/Roche; Incyte; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent pending (Inst); Patent Pending (Inst)
 
Donna Niedzwiecki
No Relationships to Disclose
 
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)
 
Fang-Shu Ou
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Federico Innocenti
No Relationships to Disclose
 
Alan P. Venook
Honoraria - Gilead Sciences
Consulting or Advisory Role - Gilead Sciences; Merrimack
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Merck Serono; Merrimack; Roche; Taiho Pharmaceutical